Access to high-cost drugs: Decision makers' perspectives

Journal of Pharmacy Practice and Research

Volumn 35, Issue 1, 2005, Pages 18-20

  Gallego, Gisselle ^a   Melocco, Terry ^b   Taylor, Susan J ^a   Brien, Jo Anne E ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; ATTITUDE; AUSTRALIA; BUDGET; DECISION MAKING; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE ACCESS; HOSPITAL ADMINISTRATOR; HOSPITAL PHYSICIAN; INTERVIEW; PHARMACIST; PUBLIC HOSPITAL; RESOURCE ALLOCATION;

EID: 18444400569     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2005.tb00294.x     Document Type: Article

References (22)

1. Commonwealth Department of Health and Aged Care. The Australian health care system, an outline. Canberra: Commonwealth Department of Health and Aged Care; 2000.
2. Victorian Government Department of Human Services. Victoria-public hospitals and mental health services policy funding guidelines 2002-2003. Melbourne: Victorian Government Department of Human Services; 2002. Available from 〈www.health.vic.gov.au/pfg2002/sectiona.pdf〉.
3. Donate R, Scotton R. The Australian health care system. In: Mooney G, Scotton R, editors. Economics and Australian health policy. St Leonards: Allen & Unwin; 1999. p. 20-39.
4. Royal Australasian College of Physicians. Response to the senate inquiry into public hospital funding. Sydney: Royal Australasian College of Physicians; 1999.
5. Australian Institute of Health and Welfare (AIHW). Health expenditure Australia 2001-02. Health and Welfare Expenditure Series No. 17. Canberra: AIHW; 2003.
6. Tan EL, Day RO, Brien JE. Drug and therapeutics committees - are they fulfilling their potential to improve the quality use of medicines? Int J Pharm Pract 2003; 11: 175-81.
7. Pacey S, Li Wan Po A. A review of methods of drug cost management in hospitals. J Clin Pharm Ther 1958; 23: 171-7.
8. Gallego G, Taylor S, Brien JE. Equity of access to high cost drugs (HCDs): a case study [abstract]. Abstracts of the 8th World Congress on Clinical Pharmacology and Therapeutics. Clin Exp Pharmacol Physiol 2004; 31 (suppl. 1): S80-S129.
9. Glennie JL, Woloschuck DM, Hall KW. High technology drugs for cancer. The decision process for adding to a formulary. Pharmacoeconomics 1993; 4: 405-13.
10. Uretsky SD, Kaatz BL. Adding an expensive drug to the formulary. Am J Hosp Pharm. 1993; 50: 1667-71.
11. Capp S, Savage S, Clarke V. Exploring distributive justice in health care. Aust Health Rev 2001; 24: 40-4.
12. Gallego G, Melocco T, Taylov SJ, Brien JE. Impact of high-cost drugs for individual patient use. J Pharm Pract Res 2004; 34: 100-3.
13. Hadom DC. Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue. JAMA 1991; 265: 2218-25.
14. Wight J, Richards M. Very high cost treatment for a single individual-a case report. J Public Health Med 2003; 25: 4-7.
15. Lindblad AK, Hartzema AG, Jansson L, Feltelius N. Patients' views of priority setting for new medicines. A qualitative study of patients with rheumatoid arthritis. Scand J Rheumatol 2002; 31: 324-9.
16. Thompson AJ. Inequality in the availability of expensive treatments. J R Coll Physicians Lond 1999; 33: 448-9.
17. Foy R, So J, Rous E, Scarffe JH. Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold. BMJ 1999; 318: 456-9.
18. Mucklow JC. How can we afford costly medicines? J R Coll Physicians Lond 2000; 34: 124-7.
19. Sharp D. Country profile: Australia. Lancet 1998; 351: 1569-78.
20. Allinson Y. Funding of pharmaceuticals in public hospitals: PBS under the probe. Healthcover 2001; 11: 58-53.
21. Ross J. The use of economic evaluation in health care: Australian decision makers' perceptions. Health Policy 1995; 31: 103-10:
22. Minichiello V, Aroni R, Timewell E, Alexander L. In-depth interviewing: principles, techniques, analysis. 2nd ed. Melbourne: Longman; 1995.